Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

Vertex Pharmaceuticals Inc. Annual cash flow by MarketWatch. View VRTX net cash flow, operating cash flow, operating expenses and cash dividends.

It has strategic partnerships with Vertex Pharmaceuticals Incorporated, Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug ...

Vertex Pharmaceuticals is the global leader in ... Vertex is an ideal tariff-proof stock, since the company produces most of its CF drugs in the U.S. The company also says its supply chain is ...

According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $515.04. Vertex Pharmaceuticals stock opened at $445.85 on ...

This stock is Vertex Pharmaceuticals (NASDAQ: VRTX), a biotech that's delivered a long track record of growth and profitability thanks to its leadership in the cystic fibrosis (CF) treatment market.

Vertex Pharmaceuticals (NASDAQ ... This event is seen as a potential catalyst for the stock, with success potentially opening up a large market opportunity in chronic pain management.

This stock is Vertex Pharmaceuticals (NASDAQ: VRTX), a biotech that's delivered a long track record of growth and profitability thanks to its leadership in the cystic fibrosis (CF) treatment market.

Agios Pharmaceuticals reported revenues of $8.73 million in the last reported quarter, representing a year-over-year change of +6.6%. EPS of -$1.55 for the same period compares with -$1.45 a year ago.